Do Albert, Reau Nancy S
Section of Digestive Diseases Department of Internal Medicine Yale School of Medicine New Haven CT.
Section of Hepatology Rush University Medical Center Chicago IL.
Hepatol Commun. 2020 Jan 20;4(3):329-341. doi: 10.1002/hep4.1480. eCollection 2020 Mar.
The past decade has seen transformation in the strategies for identifying and managing viral hepatitis, most dramatically the transformation of hepatitis C virus from a mostly chronic affliction to a curable disease that is accessible to wide populations through direct-acting antiviral therapies. More recently, shifting of hepatitis C virus burden to younger patients driven by intravenous drug use has shaped screening recommendations. Future work focusing on effective screening, linkage to care, treatment initiation, and post-cure management will allow countries to work toward meeting goals of eliminating viral hepatitis as a major public health threat. Concurrently, hepatitis B virus has also seen advances in management using oral nucleos(t)ide therapies with high-resistance barriers. However, virologic cure remains elusive in the setting of viral genetic persistence within the hepatocyte nucleus, even with suppressive antiviral therapy. Future directions include a refined definition of "cure," new biomarkers, and development of therapies targeting multiple pathways in the viral pathogenic and replication pathway. Progress is additionally being made on the management of hepatitis D infection. This review summarizes the recent evolution in disease characteristics, associated affected population, and changes in our understanding of management for these infections. We also discuss future directions in the management of viral hepatitis, including discussion on issues related to management before and after antiviral therapy. : We summarize recent advances in the identification and management of viral hepatitis, which hold the potential to markedly reduce disease burden and therefore associated liver-related complications. However further work is needed to adequately identify and manage these diseases.
过去十年间,病毒性肝炎的识别与管理策略发生了变革,最显著的是丙型肝炎病毒从一种大多为慢性的疾病转变为一种可治愈的疾病,通过直接抗病毒疗法,广大人群都可获得治疗。最近,静脉吸毒导致丙型肝炎病毒负担向年轻患者转移,这影响了筛查建议。未来聚焦于有效筛查、与治疗的衔接、治疗启动及治愈后管理的工作,将使各国朝着实现消除病毒性肝炎这一重大公共卫生威胁的目标迈进。同时,在使用具有高耐药屏障的口服核苷(酸)疗法管理乙型肝炎病毒方面也取得了进展。然而,即使进行抑制性抗病毒治疗,在肝细胞细胞核内病毒基因持续存在的情况下,病毒学治愈仍然难以实现。未来的方向包括对“治愈”的精确界定、新的生物标志物以及开发针对病毒致病和复制途径中多种途径的疗法。在丁型肝炎感染的管理方面也取得了进展。本综述总结了这些感染在疾病特征、相关受影响人群以及我们对管理的认识变化方面的最新演变。我们还讨论了病毒性肝炎管理的未来方向,包括抗病毒治疗前后管理相关问题的讨论。我们总结了病毒性肝炎识别与管理方面的最新进展,这些进展有可能显著减轻疾病负担以及相关的肝脏并发症。然而,仍需要进一步开展工作以充分识别和管理这些疾病。